Stock report · Delisted · Nasdaq
Allovir Inc (ALVR)
11.47USD Delisted Final close · Mar 19, 2025
ALVR no longer trades. Allovir Inc was delisted from the Nasdaq in March 2025.
All prices on this page are historical. The last trade was on March 19, 2025, at $11.47.
ALVR stock price history
Final trading statistics
- Final close
- $11.47
- Final trading day
- Mar 19, 2025
- Market cap at delisting
- $57.85M
- Shares outstanding
- 5.04M
- Final 52-week range
- $0.38 – $12.78
- Avg. volume (final 3 mo.)
- 23,570
- All-time high
- $1076.63 · Dec 2020
- All-time low
- $8.76 · Jan 2025
- Return since IPO
- -98.0%
- Beta
- 0.62
- Book value / share
- $22.60
- Price / book
- 0.51
About Allovir Inc
Allovir was a clinical-stage cell therapy company. It researched and developed ready-made, donor-derived T cell therapies that target multiple viruses (VSTs), aimed at preventing and treating serious virus-related diseases.
Its lead product, posoleucel, targeted BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus. Other candidates included ALVR106 for RSV, influenza, parainfluenza and human metapneumovirus; ALVR109 for SARS-CoV-2 and COVID-19; ALVR107 for hepatitis B; and ALVR108.
Formerly ViraCyte, Inc., it became Allovir in May 2019. The company was incorporated in 2013 and based in Waltham, Massachusetts. Its stock was delisted from the Nasdaq in March 2025, with the last trade on March 19, 2025 at $11.47.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Waltham, MA
- Employees
- 6
- IPO date
- July 30, 2020
- Delisted
- March 19, 2025
- SEC CIK
- 1754068
Allovir financials before the delisting
The last 5 fiscal years Allovir reported as a public company, fiscal year ending December.
ALVR revenue and net income
ALVR earnings per share
ALVR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | −$58.8M | −$3.98 |
| FY2023 | $0.00 | −$190.4M | −$1.67 |
| FY2022 | $0.00 | −$168.7M | −$2.25 |
| FY2021 | $0.00 | −$172.0M | −$2.74 |
| FY2020 | $0.00 | −$68.4M | −$5.17 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Allovir stock FAQ
What happened to Allovir stock?
Allovir Inc was delisted from the Nasdaq in March 2025. The final close was $11.47 on March 19, 2025.
Can I still buy ALVR stock?
No. ALVR is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on March 19, 2025.
What was the last price of ALVR?
ALVR last closed at $11.47 on March 19, 2025, which valued the company at about $57.85M.
How did Allovir do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Allovir reported revenue of $0.00 and net income of −$58.8M.
When did Allovir go public?
Allovir shares started trading on July 30, 2020.
ALVR no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.